Morocco's Pharma 5 Unveils Groundbreaking Cannabis-Based Epilepsy Drug (video)

Pharma 5 has launched Morocco's first locally-produced CBD medication, "CANNABIDIOL PHARMA 5," aimed at treating epilepsy in around 400,000 patients. The drug targets those with drug-resistant forms, like Lennox-Gastaut and Dravet syndromes, and is expected for distribution in 2025. This initiative enhances Morocco's pharmaceutical status and medical cannabis potential.

HASSAN BENYOUB HASSAN BENYOUB
0
Morocco's Pharma 5 Unveils Groundbreaking Cannabis-Based Epilepsy Drug (video)
cannabidiol

In a landmark development for Morocco's pharmaceutical industry, Pharma 5 laboratories have announced the creation of the country's first locally-produced medication containing cannabidiol (CBD), a non-psychoactive compound extracted from cannabis. This innovative drug, designed to treat epilepsy, marks a significant milestone in the nation's medical and agricultural sectors.

https://x.com/ouamoussi/status/1870437816074641830

A New Hope for Epilepsy Patients

The new medication, registered under the name "CANNABIDIOL PHARMA 5," aims to provide relief to approximately 400,000 Moroccans suffering from epilepsy, including 100,000 children[1][5]. Developed as a generic version of the original drug EPIDYOLEX produced by British laboratories GW, this breakthrough treatment specifically targets patients with drug-resistant epilepsy[5][7].

Key Features of the New Drug

  • 100% Moroccan Production: From seed cultivation to final product manufacturing, the entire process takes place within Morocco[1].
  • Investment: Pharma 5 invested 250 million dirhams in this project, with 25% allocated to research and development[1].
  • Composition: The medication contains cannabidiol (CBD) extracted locally and is free from THC, the psychoactive component of cannabis[1].
  • Target Conditions: Primarily aimed at treating Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy[4].

Availability and Distribution

  • Expected Launch: The drug is slated for distribution in the first half of 2025[1].
  • Prescription Only: It will be available only through neurologists' prescriptions[1].
  • Reimbursement: The medication is expected to be covered by health insurance, pending price determination by the Directorate of Medicines and Pharmacy (DMP)[1].

Impact and Significance

This development not only represents a major advancement in Morocco's pharmaceutical capabilities but also aligns with the country's vision to leverage its cannabis resources for medical and economic benefits. The project showcases Morocco's commitment to fostering innovation in healthcare while adhering to international quality standards[1][5].

Looking Ahead

As Morocco positions itself at the forefront of medical cannabis research and production, this new epilepsy drug could pave the way for further developments in cannabis-based medicines. The success of this initiative may open doors to exploring other potential medical applications of cannabis, contributing to both patient care and economic growth in the country.

Tags: